logo

News

08 Aug 2018

Principle Scientist/Senior Scientist, Discovery Biology

Position: Principle Scientist/Senior Scientist, Discovery Biology Location: Shanghai Job Summary: Principle Scientist and Senior Scientist with expertise in in vitro/in vivo pharmacology in oncology and immune-oncology, will provide scientific leadership and expertise to support multiple immunoOncology projects. The candidate must be competent to interact with cross-functional discovery project team. The person should actively strengthen the cancer immunotherapy pipeline through championing internal projects and managing/supporting collaborations with external partners.   Responsibility Design, execute and interpret studies on the development of biologic […]

08 Aug 2018

Associate scientist/scientist in Protein purification

Position: Associate scientist/scientist in Protein purification Location: Shanghai Job Summary:   Responsibility 1.Expression and purification of monoclonal antibody and bispecific antibody, and optimization of process. 2.The characterization of purified antibodies, such as SDS-PAGE, SEC-HPLC, ELISA, affinity, etc. 3.Complete the antibody expression, purification and characterization under supervision. 4.Process the raw data to generate reports. 5.Take part in laboratory routine and others related to the projects. Qualification: Bachelor degree or above in life science or related fields, such as biochemistry and molecular […]

08 Aug 2018

Principle Scientist/Senior Scientist (Antibody Discovery)

Position: Principle Scientist/Senior Scientist (Antibody Discovery) Location: Shanghai Job Summary: The candidate will be responsible for leading antibody discovery projects from hit generation to lead optimization stage. The candidate will not only lead internal efforts but also work closely with outside collaborators. Responsibility The position requires in depth experience in therapeutics antibody discovery. This includes antigen design, assay development, antibodies characterization, sequences analysis and optimization, etc. Experience in phage library construction and selection is a plus. Qualification: Minimum requirements: PhD […]

06 Aug 2018

Scientist/Associate Scientist (Hybridoma platform)

Position: Scientist/Associate Scientist (Hybridoma platform) Location: Shanghai Job Summary: This position will involve research in the area of antibody discovery, in which the researcher will be responsible for therapeutic antibody generation by hybridoma platform as well as support of EpimAb pipeline. Responsibility: Coordination of animal immunization. Hybridoma fusion and monoclonal antibody generation. High throughput antibody screening. Affinity ranking and measurement. Antibody characterization by functional assays. Qualification: S. degree in biology, immunology, or other related major with 2+ years working experience, […]

06 Aug 2018

BD Director

Position: BD Director Location: Shanghai Report to: CB0/C00 We are seeking a highly motivated Business Development Director hat will be based in our Shanghai offices to support our local China BD efforts. Roles and Responsibilities: The successful candidate will play a key role in the local growth strategy of EpimAb and its implementation The position will be interacting with the Chinese Government, local China pharmaceutical companies, current partners of EpimAb, CROs, CDMOs and other entities The role will also be […]

23 Apr 2018

EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program

Zhejiang Teruisi Biopharmaceutical to take the lead in developing the program in China, Epimab retains worldwide commercial rights outside of China Shanghai/Suzhou, and Huzhou, China, April 23, 2018 – EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Zhejiang Teruisi Biopharmaceutical, a company specialized in the development of biologics, today announced a development collaboration on a bispecific antibody program discovered by EpimAb. Under the terms of the agreement, Zhejiang Teruisi Biopharmaceutical, Inc. will gain access to EpimAb’s Fabs-In-Tandem […]

27 Feb 2018

EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical Officer

Former Global Head of Oncology Translational Medicine at Novartis in China to Guide Transformation of EpimAb into Clinical Stage Oncology Company Shanghai, China, February 27, 2018 – EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer. Dr. Peng, former Global Head of Oncology Translational Medicine Shanghai CNIBR at Novartis, was a major contributor to the […]

10 Jul 2017

Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets

Publication from Taylor & Francis Online: In recent years, the development of bispecific antibody (bsAb) has become a major trend in the biopharmaceutical industry. By simultaneously engaging 2 molcular targets, bsAbs show unique mechanisms of action that could lead to clinical benefits unattainable by conventional monoclonal antibodies.

31 May 2017

EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead Bispecific Antibody Candidate towards Clinical Development

First FIT-Ig® Cancer Therapy Expected to Enter the Clinic in 2018 Shanghai, China, May 31, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and WuXi Biologics, a WuXi AppTec Affiliate, announced today a collaboration to advance EpimAb’s first candidate, EMB-01, towards IND-filing. EMB-01 is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. Under the agreement, WuXi will be responsible for establishing the chemistry, manufacturing and […]

25 Apr 2017

EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies

Shanghai, China, April 25, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today the completion of a $25 million Series A financing round. The financing was led by Oriza Seed Capital and included investments from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group. With the funding, Epimab will advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in immuno-oncology and other areas with a high unmet medical need. […]